Bengaluru-based Pandorum Technologies has developed a liquid cornea product that can repair damaged corneas without surgery. The injectable gel, made from biomaterials, fills corneal defects, promotes tissue regeneration, and restores vision. It has shown promising results in animal studies and early human trials. The innovation addresses the severe shortage of donor corneas in India, where over 10 million people suffer corneal blindness. The product could become a game-changer for corneal blindness treatment.

Obesity management in India is shifting toward non-surgical options as bariatric surgery remains expensive and carries risks. Medical solutions include GLP-1 agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), which reduce appetite and promote 15–20% weight loss. Lifestyle interventions—diet, exercise, behavioral therapy, and digital platforms—are increasingly effective when combined with medication. Experts emphasize sustainable habits over quick fixes, with India’s obesity market growing rapidly due to rising diabetes and lifestyle diseases.

The patent for semaglutide (active ingredient in Ozempic, Wegovy, Rybelsus) expires on March 20, 2026, in India. Over two dozen generic versions are set to launch soon from companies including Dr Reddy’s, Sun Pharma, and Zydus Lifesciences. Prices could drop 60–70% initially and up to 80–90% long-term, improving access for diabetes and obesity patients. The market for anti-obesity drugs in India is Rs 3,000–3,500 crore and expected to grow eightfold by 2030. Experts call it a game-changer for affordability.